Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes
- 816 Downloads
Epidermal growth factor receptor (EGFR)-targeting therapies dramatically modified the prognosis of stage 4 non-small-cell lung cancer. Sensitizing EGFR mutations are the best efficacy factor of these treatments. In 2006, the French National Cancer Institute launched a network of 28 centers for EGFR molecular analysis in routine practice. The aim of this retrospective study was to describe the results of routine EGFR analysis in one of these centers (Lyon University Hospital) and to assess outcomes in patients with the mutation.
EGFR mutations were analyzed for exons 18–21 by direct sequencing. The characteristics of each sample were retrospectively collected from the lab archives. Subsequent outcomes for patients harboring at least one mutation were retrospectively collected from each referring physician.
During 1 year, 792 samples were analyzed, corresponding to 753 patients. A total of 133 mutations were diagnosed in 124 samples (15.7 %), corresponding to 121 patients. Most of them (77.4 %) were sensitizing mutations and were located in exons 19 and 21. Others were resistance mutations (8.3 %) or rare mutations (14.3 %) for which effects on tyrosine kinase inhibitor (TKI) sensitivity are unknown. The rate of indeterminate results (i.e., no sequencing of the entire exon 19 or 21) was 6.3 % (n = 50 samples). The only factor statistically associated with a risk of failure was sample from bone tissue: 13.7 % gave incomplete results (i.e., no whole sequencing of exons 18–21).
Eighty-five of the 121 patients with EGFR mutations were treated with TKI. There were no differences in progression free survival (PFS) according to the type of molecule (erlotinib or gefitinib) or to the line of prescription of TKI. By contrast, exon 18 sensitizing mutations showed a worse PFS than exon 19 or 21 mutations. Finally, dose reduction was significantly more frequent in the erlotinib group than in the gefitinib group.
KeywordsLung cancer Biomarkers EGFR Tyrosine kinase inhibitors Metastasis
Conflict of interest
SC declares that he has received fees for consulting, attending a meeting, and conducting a lecture from Roche, Astra Zeneca, Lilly, Glaxo-Smith Kline, Chugai, Vitalaire, Air-Product; and also research grants were paid at his institution from Pfizer, Roche, Astra Zeneca, Lilly, Pierre-Fabre, Boeringher Ingelheim, Laidet, Chugai. Other authors have none to declare.
- 4.Somatic Mutations in Epidermal Growth Factor Receptor Database (2008). www.somaticmutations-egfr.org. Accessed 30 May 2013
- 11.Institut National du Cancer (INCA) (2010) Cancer du poumon non à petites cellules. Formes localisées non opérables, localement avancées et métastatiques. Recommandations & référentiels. www.e-cancer.fr. Accessed 30 May 2013
- 12.Keedy VL et al (2011) American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29(15):2121–2127PubMedCrossRefGoogle Scholar
- 14.Beau-Faller M et al (2011) Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project—part 1). J Thorac Oncol 6(6):1006–1015PubMedCrossRefGoogle Scholar
- 17.Fukuoka M et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–2874PubMedCrossRefGoogle Scholar
- 21.Institut National du Cancer (INCA) (2012) Molecular genetic testing for equal access to targeted therapies in France in 2011, Reports & Summaries. http://www.e-cancer.fr. Accessed 30 May 2013